Share this
Alvotech Agrees to Merge With SPAC Oaktree Acquisition Corp. II
Transaction to accelerate company’s mission of bringing cost-effective biosimilars to patients in all major markets around the globe • December 9, 2021
Exscientia – $510.4 Million IPO
October 5, 2021
Cooley Shortlisted Across Five Categories for LMG Life Sciences Americas Awards
Publication also names six Cooley partners finalists for Attorney/Litigator of the Year in respective practice areas • August 9, 2021
Legal 500 US 2021 Highlights Cooley
July 19, 2021
Chambers USA 2021 Recognizes Cooley Lawyers + Practices
May 28, 2021
Adagio Therapeutics Raises $336 Million Series C for COVID-19 Treatment and Prevention
May 20, 2021
Exscientia Inks Investment of up to $525 Million
May 10, 2021
Immunocore Closes $312.1 Million Aggregate Financing, Makes Public Debut
February 23, 2021
Opthea – $128 Million IPO
Largest IPO by a development-stage Australian life sciences company • November 3, 2020
Legal 500 US 2020 Highlights Cooley
June 24, 2020
Chambers USA 2020 Recognizes Cooley Lawyers + Practices
May 13, 2020
Cooley Advises on Follow-On Offerings for Reata + argenx
Transactions total more than $1 billion • December 5, 2019
Legal 500 US 2019 Highlights Cooley
August 29, 2019
Chambers USA 2019 RecognizesCooley Lawyers + Practices
April 30, 2019
Advanced Tech, Crossover Investors Drive Biopharma IPO Surge
Wall Street Journal Pro • October 17, 2018
Aquestive – $74 Million IPO
September 12, 2018
The Legal 500 2018 Recognizes Cooley
September 7, 2018
Liquidia – $53 Million IPO
August 21, 2018
Biotech Companies Continue IPO Hot Streak, but for How Long?
July 2, 2018
OrthoPediatrics – $60 Million IPO
December 21, 2017
ERYTECH – $144 Million IPO
November 22, 2017
Cooley Advises on Nightstar + NuCana IPOs
Pair of transactions highlight strength across life sciences sector public offerings • October 10, 2017
NEA Leads $50 Million Series C for Trevi Therapeutics
September 1, 2017
Zealand Pharma – $89 Million IPO
August 25, 2017
Ovid – $75 Million IPO
June 13, 2017
Cooley Advises on Series of Life Sciences IPOs
Zymeworks, Verona, UroGen and Biohaven IPOs highlight core strengths across the sector • May 30, 2017
Cooley Advises Underwriters on Mortgage REIT Equity Offerings
Syndicate representation in offerings by AGNC Investment Corp and Arbor Realty Trust highlight broad capabilities of Cooley’s capital markets group • May 17, 2017
ERYTECH Closes €70.5 Million Private Placement to US + European Investors
May 3, 2017
CytoSorbents – $11.5 Million Shelf Takedown
April 19, 2017
Valeritas – $53 Million IPO
April 7, 2017
Global Blood Therapeutics – $144 Million Shelf‑Takedown
March 8, 2017
Sierra Oncology – $29.5 Million Shelf-Takedown
February 23, 2017
ObsEva – $97 Million IPO
February 16, 2017
ERYTECH Closes €10 Million Private Placement
December 14, 2016
Aclaris Therapeutics – $105 Million Follow-On Offering
November 30, 2016
Ascendis Pharma – $136 Million Follow-On
November 3, 2016
Tabula Rasa – $59 Million IPO
October 25, 2016
Novan – $52 Million IPO
October 14, 2016
Catabasis – Underwritten Registered Offering
October 7, 2016
AveXis – $169 Million Follow-On Offering
September 21, 2016
Recro Pharma – $15 Million Follow-On
August 30, 2016
Advaxis – $30 Million Registered Direct Offering
Gemphire Therapeutics – $30 Million IPO
August 22, 2016
Inotek Pharmaceuticals – $50 Million Follow-On
August 18, 2016
Syros IPO – $58 Million
July 26, 2016
Selecta Biosciences – $74 Million IPO
July 25, 2016
Merus IPO – $61 Million
June 1, 2016
Oncobiologics – $40 Million IPO and Private Placement
May 19, 2016
Law360 Names Cooley "Practice Group of the Year" for Capital Markets and Privacy
December 22, 2015
Cooley Advises ERYTECH on €25.4 Million Private Placement
December 9, 2015
Strongbridge Biopharma – IPO
October 27, 2015
Aclaris Therapeutics – IPO
October 20, 2015
ProNAi – $158 Million IPO
August 7, 2015
Chiasma Completes $117 Million IPO
July 31, 2015
Celyad Completes $100 Million IPO
July 27, 2015
Catabasis Completes IPO
July 20, 2015
Cooley Advises Immunocore on Largest European Private Life Sciences Financing on Record
Cooley Adds Four Prominent Corporate Partners in New York and San Francisco
Group led by Former Head of Reed Smith's Corporate & Securities Group and Chair of US Capital Markets • July 17, 2015
Axovant Completes $362 Million IPO
June 16, 2015
Law360 Names Div Gupta a Capital Markets "Rising Star"
April 1, 2015
Inotek Pharmaceuticals – $40 Million IPO
February 23, 2015
Ascendis Pharma Closes $124 Million Initial Public Offering
February 13, 2015
Bellicum Completes $160 Million Initial Public Offering
Cooley Continues its Capital Markets Leadership, Advising on a Record 100 Public Offerings in 2014
February 9, 2015
OnCore Biopharma Announces Merger Agreement with Tekmira Pharmaceuticals
January 14, 2015
DBV Technologies Completes Concurrent Public Offerings
November 6, 2014
Vitae Pharmaceuticals Completes Initial Public Offering
October 10, 2014
Cooley's Capital Markets Leadership Continues through 1H 2014
August 26, 2014
Cooley Advises Underwriters on T2 Biosystems IPO
August 22, 2014
Cooley Advises Underwriters on Immune Design IPO
August 11, 2014
Cooley Grows Capital Markets Group with New York Partner Addition
March 10, 2014